



## ASX ANNOUNCEMENT

### Appointment of Chief Financial Officer

- *Barrie Lambert appointed as Chief Financial Officer for Lumos*
- *Senior finance professional with experience across health technology businesses, including prior experience with Lumos*

**Melbourne, VIC. (16 February 2022)** - Lumos Diagnostics (ASX: LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, today announces that Barrie Lambert has been appointed as Chief Financial Officer (CFO) for the Company.

Barrie Lambert has extensive experience in leading rapid growth global, publicly traded companies and, for the past five years has been the CFO of Planet Innovation, one of the founding shareholders in Lumos Diagnostics. As a consequence of his role in Planet Innovation, Barrie is familiar with the historical operations and finances of Lumos Diagnostics and was involved in supporting Lumos’ with its Initial Public Offering.

Prior to his role at Planet Innovation, Barrie served in CEO and CFO roles in a technology business with operations in Australia, United States, New Zealand and United Kingdom and spent more than six years living and working in San Francisco as the VP and General Manager of the Louis Vuitton business unit, Sephora.

Lumos Diagnostics Executive Chair, Sam Lanyon, noted, “Barrie brings broad and deep finance and executive leadership experience, specifically within rapidly scaling companies such as Planet Innovation and Lumos Diagnostics. We are delighted to welcome Barrie to the role of CFO.”

In this global role, Barrie will focus his efforts across the business including extensive periods in the US working closely with Lumos finance and executive leadership teams.

This announcement was approved by the Lumos Disclosure Committee.

###

**About Lumos Diagnostics**

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com) or call +1 941-556-1850.

**Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

**Media Contact:**

Matthew Wright – Australia  
Director, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 (0) 451 896 420

**Investor Contact:**

Matthijs Smith – Lumos Diagnostics  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 137 080  
+61 3 9087 1598

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205  
+61 3 9087 1598